Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Enlivex Ltd. (ENLV): Examining Macrophage Reprogramming Therapies

Enlivex Ltd. (ENLV): Examining Macrophage Reprogramming Therapies

Key Takeaways

  • ENLV is Enlivex Ltd., a clinical-stage Israeli biotechnology company developing macrophage-reprogramming cell therapies.
  • The company's lead candidate, Allocetra, is an off-the-shelf cell therapy designed to restore macrophages — a type of immune cell — to a healthy, homeostatic state.
  • Enlivex is advancing Allocetra primarily in knee osteoarthritis and sepsis-related organ failure, with earlier-stage work in temporomandibular joint (TMJ) osteoarthritis and solid tumors.
  • As a clinical-stage company, Enlivex has no approved products and generates no product revenue; its value depends heavily on future clinical trial results.
  • The company is headquartered in Ness Ziona, Israel, was founded in 2005, and employs roughly 34 people.

Company Background

Enlivex Ltd. (ENLV) operates as a small, clinical-stage biotechnology firm centered on macrophage reprogramming. Macrophages serve as key white blood cells in the immune response to infection, injury, and disease. The core concept here involves situations where these cells shift into an overactive, harmful state, and the aim is to bring them back to a balanced condition to address underlying issues. I follow ENLV due to its focus on sizable markets with limited options, though it remains a high-risk, pre-revenue name in biotech.

Business and Pipeline Details

Founded in 2005 and based in Ness Ziona, Israel, Enlivex trades on the NASDAQ Capital Market without any marketed products or product revenue to date. Its efforts revolve around the Allocetra platform, an allogeneic cell therapy produced from healthy donor cells. This off-the-shelf approach allows storage and administration without patient-specific customization, setting it apart from many personalized options. The therapy seeks to return macrophages to homeostasis, targeting inflammation and immune imbalance at the source rather than just easing symptoms.

Development spans several areas, with the most advanced work in knee osteoarthritis, a widespread condition where disease-modifying treatments are still scarce. Additional programs address organ dysfunction from sepsis and earlier efforts in TMJ osteoarthritis plus solid tumors. A prior collaboration with BeiGene explored Allocetra alongside an immune checkpoint inhibitor in advanced solid tumors. Funding has come mainly from equity and debt raises, with spending centered on R&D. The off-the-shelf model offers a potential edge in scalability, though competition includes larger players with broader resources.

Investor Interest Factors

Attention centers on the substantial unmet needs in target markets and the technology's possible differentiation. Osteoarthritis affects millions globally, with most therapies focused on symptom relief instead of changing disease progression. A treatment that could modify the course would open a meaningful opportunity. Sepsis drives many hospital deaths with few targeted options available, so a macrophage-focused method to resolve immune dysfunction could mark a notable step forward. The manufacturing approach may also prove more practical for broader use than individualized therapies.

As a smaller company with a concentrated pipeline, the stock reacts strongly to clinical updates, regulatory news, and financing activity. One notable point is the Regenerative Medicine Advanced Therapy designation from the FDA for Allocetra in age-related knee osteoarthritis, which can help accelerate development and review.

Risk Considerations

Investing in ENLV involves notable binary risks common to clinical-stage biotechs. No products are approved, revenue is absent, and outcomes rest almost entirely on trial results. Unfavorable data could shift the outlook substantially. Most experimental therapies do not reach the market, and approval is never assured. Larger competitors with more resources add pressure, and reliance on capital markets for funding can lead to dilution. The modest team size and single-platform focus tie performance closely to one technology, making this a speculative holding suited mainly to those comfortable with volatility.

Research Tools in Practice

When evaluating names like this, I often run quick comparisons through Tickeron’s AI Screener to check how ENLV stacks up against peers on key metrics and patterns. It helps surface context without replacing deeper due diligence.

Conclusion

Enlivex Ltd. (ENLV) stands out in biotech through its macrophage-reprogramming focus and off-the-shelf cell therapy platform. Allocetra targets sizable areas with clear needs, such as knee osteoarthritis and sepsis-related complications. Still, as a pre-revenue clinical-stage entity, its path depends on trial results, regulatory steps, and capital access. This makes it a name of interest for those following emerging immunotherapies while accepting the associated risks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ENLV

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


ENLV sees its Stochastic Oscillator ascends from oversold territory

On November 18, 2026, the Stochastic Oscillator for ENLV moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 57 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in 158 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for ENLV entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.006) is normal, around the industry mean (3.596). P/E Ratio (0.001) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions

Industry Biotechnology

Industry
Medical Specialties
Address
14 Einstein Street
Phone
+972 86328500
Employees
34
Web
https://www.enlivex.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.